Mega menu

Home
Product regulation
Product regulation

Understand your obligations and access industry Guidance and other information about the products we regulate.
Safety and shortages
Safety and shortages

Access information about product recalls, shortages and other alerts, and learn how we manage safety.
Resources and guidance
Resources and guidance

Get information to help you understand our work, regulations and industry obligations.
Business services
Business services

Access our systems to submit applications, manage forms, make payments and communicate securely.

Sandoz Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

(-) Cancellation by sponsor (351)
ARTG (709)
Prescription medicine registration (62)
Section 14, TGO91 consent (17)
Cancellation or suspension (8)
Australian public assessment report (AusPar) (6)
Prescription medicine decision summary (1)

Date

2025 (20)
2024 (62)
2023 (14)
2022 (17)
2021 (71)
2020 (71)
2019 (29)
2018 (30)
2017 (30)
2015 (7)

Search

Filters applied:

Cancellation by sponsor

Clear all

Sponsor content

351 result(s) found, displaying 321 to 330

ROPIVACAINE SANDOZ ropivacaine hydrochloride (as monohydrate) 40mg/20mL solution for injection ampoule Cancelled under s30(1)(c)

30 June 2017

Cancellation by sponsor

Requested by Sandoz Pty Ltd
ROPIVACAINE SANDOZ ropivacaine hydrochloride (as monohydrate) 100mg/10mL solution for injection ampoule Cancelled under s30(1)(c)

30 June 2017

Cancellation by sponsor

Requested by Sandoz Pty Ltd
ROPIVACAINE SANDOZ ropivacaine hydrochloride (as monohydrate) 150mg/20mL solution for injection ampoule Cancelled under s30(1)(c)

30 June 2017

Cancellation by sponsor

Requested by Sandoz Pty Ltd
ROPIVACAINE SANDOZ ropivacaine hydrochloride (as monohydrate) 20mg/10mL solution for injection ampoule Cancelled under s30(1)(c)

30 June 2017

Cancellation by sponsor

Requested by Sandoz Pty Ltd
OXALIPLATIN EBEWE oxaliplatin 50 mg/10 mL concentrated injection vial Cancelled under s30(1)(c)

30 June 2017

Cancellation by sponsor

Requested by Sandoz Pty Ltd
OXALIPLATIN EBEWE oxaliplatin 200 mg/40 mL concentrated injection vial Cancelled under s30(1)(c)

30 June 2017

Cancellation by sponsor

Requested by Sandoz Pty Ltd
OXALIPLATIN EBEWE oxaliplatin 100 mg/20 mL concentrated injection vial Cancelled under s30(1)(c)

30 June 2017

Cancellation by sponsor

Requested by Sandoz Pty Ltd
CEFEPIME SANDOZ cefepime (as hydrochloride) 2 g powder for injection vial Cancelled under s30(1)(c)

30 June 2017

Cancellation by sponsor

Requested by Sandoz Pty Ltd
CEFEPIME SANDOZ cefepime (as hydrochloride) 1 g powder for injection vial Cancelled under s30(1)(c)

30 June 2017

Cancellation by sponsor

Requested by Sandoz Pty Ltd
REMIFENTANIL SANDOZ remifentanil (as hydrochloride) 1mg powder for injection vial Cancelled under s30(1)(c)

30 June 2017

Cancellation by sponsor

Requested by Sandoz Pty Ltd

Pages

First page
Previous page
…
Page 28
Page 29
Page 30
Page 31
Page 32
Current page 33
Page 34
Page 35
Page 36
Next page
Last page

Using our website

Accessibility
Privacy
Security
Disclaimer
Copyright
Freedom of information
Acronyms and glossary terms

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Email subscriptions
Contact us
Facebook
(formerly Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health, Disability and Ageing acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.